← Back to patent-cliff list
RAP-219
Tier C — Watch / tradeRAP-219
Rapport Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TARPγ8
Indications (approved)：Seizure, Epilepsy, Partial-onset seizure, Mania, 神经痛, 双相情感障碍及相关障碍
Regional status
US
Phase III
2026-06-05
EU
Phase III
2026-08-17
China
Phase III
2026-09-10
Japan
Phase III
2026-08-17
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RAP-219?
Approved indications include: Seizure, Epilepsy, Partial-onset seizure, Mania, 神经痛, 双相情感障碍及相关障碍.
When does the RAP-219 patent expire?
No public expiry year is available for RAP-219 yet; this page updates once verified.
How do I get a quote for RAP-219 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29